JP7366166B2 - patch - Google Patents

patch Download PDF

Info

Publication number
JP7366166B2
JP7366166B2 JP2022002170A JP2022002170A JP7366166B2 JP 7366166 B2 JP7366166 B2 JP 7366166B2 JP 2022002170 A JP2022002170 A JP 2022002170A JP 2022002170 A JP2022002170 A JP 2022002170A JP 7366166 B2 JP7366166 B2 JP 7366166B2
Authority
JP
Japan
Prior art keywords
adhesive
patch
mass
adhesive layer
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022002170A
Other languages
Japanese (ja)
Other versions
JP2022036194A (en
Inventor
亮 田中
秀明 大橋
就英 三好
滝登 島
直子 藤田
康也 道中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Publication of JP2022036194A publication Critical patent/JP2022036194A/en
Priority to JP2023174989A priority Critical patent/JP2023184531A/en
Application granted granted Critical
Publication of JP7366166B2 publication Critical patent/JP7366166B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Description

本発明は貼付剤に関する。 The present invention relates to a patch.

ジメチルスルホキシド(DMSO)は、製剤において、薬物を溶解させるために使用される。例えば、特許文献1には、DMSOを溶解剤として用いるジクロフェナクナトリウムの貼付剤が開示されている。 Dimethyl sulfoxide (DMSO) is used in formulations to dissolve drugs. For example, Patent Document 1 discloses a diclofenac sodium patch using DMSO as a dissolving agent.

国際公開第2013/191128号International Publication No. 2013/191128

一般に、貼付剤の付着性は時間ともに徐々に低下する。本発明者らは、DMSOを貼付剤の粘着剤層に配合すると、貼付剤に粘着性をもたらす組成物が可塑化し、粘着剤層の粘着性が低下することを見出した。そして、DMSOを含有する貼付剤を長時間(例えば、24時間)適用すると、十分な付着性が最後まで持続せず、治療が完了する前に貼付剤が剥がれてしまうおそれがあることを、本発明者らは見出した。 Generally, the adhesiveness of a patch gradually decreases over time. The present inventors have discovered that when DMSO is blended into the adhesive layer of a patch, the composition that provides the adhesiveness to the patch becomes plasticized, and the adhesiveness of the adhesive layer decreases. Furthermore, it is important to note that if a patch containing DMSO is applied for a long time (e.g., 24 hours), sufficient adhesion may not last until the end, and the patch may peel off before the treatment is complete. The inventors found out.

本発明者らは、DMSOを含有する粘着剤層を、特定の透湿性を備える支持体と組み合わせることで、長時間貼付後の貼付剤の付着性が大幅に向上することを見出し、本発明を完成するに至った。 The present inventors have discovered that by combining an adhesive layer containing DMSO with a support having a specific moisture permeability, the adhesion of the patch after long-term application is significantly improved, and the present invention has been developed based on this finding. It has been completed.

本発明の貼付剤は、支持体層と支持体層上に積層された粘着剤層とを備え、支持体層の透湿度は400g/m・24時間以上であり、粘着剤層は、薬物と、DMSOと、粘着剤とを含む。支持体層の透湿度は、750g/m・24時間以上であってよく、2000g/m・24時間以上であってよい。 The adhesive patch of the present invention comprises a support layer and an adhesive layer laminated on the support layer, the support layer has a moisture permeability of 400 g/ m2 ·24 hours or more, and the adhesive layer , DMSO, and an adhesive. The moisture permeability of the support layer may be 750 g/m 2 ·24 hours or more, or 2000 g/m 2 ·24 hours or more.

粘着剤層は、ゴム系粘着剤、アクリル系粘着剤及びシリコーン系粘着剤から選択される少なくとも一つの粘着剤を含んでもよく、スチレン-イソプレン-スチレンブロック共重合体を含んでもよい。 The adhesive layer may include at least one adhesive selected from a rubber adhesive, an acrylic adhesive, and a silicone adhesive, and may include a styrene-isoprene-styrene block copolymer.

薬物は、ケトプロフェン、ジクロフェナクナトリウム、及びインドメタシンからなる群より選択される1種以上の薬物であってよい。また、粘着剤層は有機酸を含んでもよい。 The drug may be one or more drugs selected from the group consisting of ketoprofen, diclofenac sodium, and indomethacin. Further, the adhesive layer may contain an organic acid.

本発明の貼付剤によれば、高い透湿度を有する支持体層を用いることにより、十分な付着性が長時間持続する。そのため、長時間(例えば、24時間)適用しても貼付剤が剥がれ落ちにくい。その結果、薬物が鎮痛かつ抗炎症作用を有する薬物、例えば、ケトプロフェン、ジクロフェナクナトリウム又はインドメタシンである場合には、貼付剤を24時間患者の皮膚に貼付したときに十分な累積皮膚透過量がより確実に得られる。また、薬物の最大血漿中濃度Cmaxがより確実に達成される。したがって、本発明の貼付剤によれば、より効果的な薬物治療が可能となる。 According to the adhesive patch of the present invention, sufficient adhesion can be maintained for a long time by using a support layer having high moisture permeability. Therefore, the patch is difficult to peel off even if it is applied for a long time (for example, 24 hours). As a result, when the drug is a drug with analgesic and anti-inflammatory effects, such as ketoprofen, diclofenac sodium, or indomethacin, sufficient cumulative skin permeation is more assured when the patch is applied to the patient's skin for 24 hours. can be obtained. Moreover, the maximum plasma concentration Cmax of the drug is more reliably achieved. Therefore, the adhesive patch of the present invention enables more effective drug treatment.

支持体層の透湿度と、粘着剤層の全質量に対するDMSOの質量%濃度(以下、「DMSO濃度」という)の低下速度との関係を示すグラフである(試験例1)。2 is a graph showing the relationship between the water vapor permeability of the support layer and the rate of decrease in the mass % concentration of DMSO (hereinafter referred to as "DMSO concentration") with respect to the total mass of the adhesive layer (Test Example 1). 支持体層の透湿度と、粘着剤層の全質量に対するDMSOの質量%濃度の半減期との関係を示すグラフである(試験例1)。It is a graph showing the relationship between the water vapor permeability of the support layer and the half-life of the mass % concentration of DMSO with respect to the total mass of the adhesive layer (Test Example 1).

本発明の貼付剤は、支持体層と支持体層上に積層された粘着剤層とを備える。粘着剤層は、通常、支持体層の一方の面に積層され、必要に応じて、粘着剤層のもう一方の面に剥離可能なフィルムが積層される。 The adhesive patch of the present invention includes a support layer and an adhesive layer laminated on the support layer. The adhesive layer is usually laminated on one side of the support layer, and if necessary, a releasable film is laminated on the other side of the adhesive layer.

まず、粘着剤層について説明する。粘着剤層は、貼付剤適用時に皮膚に圧着する部位であり、薬物と、DMSOと、粘着剤とを少なくとも含む。 First, the adhesive layer will be explained. The adhesive layer is a part that is pressed onto the skin when the patch is applied, and contains at least a drug, DMSO, and an adhesive.

薬物はDMSOに溶解性の成分である。薬物は、ロキソプロフェン、フェルビナク、フルルビプロフェン、インドメタシン、ケトプロフェン、及び、ジクロフェナクナトリウム等の鎮痛かつ抗炎症作用を有する薬物であってよく、ブプレノルフィン、フェンタニル、及び、ブトルファノールなどの鎮痛薬又は麻薬、クロニジン、エストラジオール、ツロブテロール、オキシブチニンなどその他の薬物であってよい。薬物の含有量は、粘着剤層の全質量に対して、例えば、1質量%~20質量%又は2質量%~10質量%である。 The drug is a component that is soluble in DMSO. The drug may be a drug with analgesic and anti-inflammatory properties such as loxoprofen, felbinac, flurbiprofen, indomethacin, ketoprofen, and diclofenac sodium; analgesics or narcotics such as buprenorphine, fentanyl, and butorphanol; clonidine; , estradiol, tulobuterol, oxybutynin, and other drugs. The content of the drug is, for example, 1% to 20% by weight or 2% to 10% by weight based on the total weight of the adhesive layer.

DMSOは薬物を溶解させて、薬物の皮膚透過性を向上させる一方、粘着剤層の粘着性の低下を招く。これらのバランスをとる点から、DMSOの含有量は、粘着剤層の全質量に対して、1質量%~20質量%であることが好ましく、1質量%~15質量%であることがより好ましく、2質量%~10質量%であることがさらに好ましく、3質量%~10質量%であることが特に好ましい。 DMSO dissolves the drug and improves the skin permeability of the drug, but it also causes a decrease in the tackiness of the adhesive layer. From the viewpoint of balancing these, the content of DMSO is preferably 1% by mass to 20% by mass, more preferably 1% by mass to 15% by mass, based on the total mass of the adhesive layer. , more preferably 2% to 10% by weight, particularly preferably 3% to 10% by weight.

薬物とDMSOの比は薬物によって異なるが、例えば薬物としてジクロフェナクナトリウムを含有する場合、貼付直前の貼付剤における粘着剤層において、含有されるジクロフェナクナトリウムの質量とDMSOの質量の比は、ジクロフェナクナトリウムの皮膚透過性を向上させる点、及びジクロフェナクナトリウムの結晶の析出を防止する点から、1:0.3~1:4であることが好ましく、1:0.4~1:3であることがより好ましく、1:0.6~1:3であることがさらに好ましく、1:0.72~1:3であることが特に好ましい。 The ratio of drug to DMSO varies depending on the drug, but for example, when diclofenac sodium is contained as a drug, the ratio of the mass of diclofenac sodium to the mass of DMSO in the adhesive layer of the patch immediately before application is equal to that of diclofenac sodium. From the viewpoint of improving skin permeability and preventing precipitation of crystals of diclofenac sodium, the ratio is preferably 1:0.3 to 1:4, more preferably 1:0.4 to 1:3. The ratio is preferably 1:0.6 to 1:3, more preferably 1:0.72 to 1:3.

粘着剤は、ゴム系粘着剤、アクリル系粘着剤及びシリコーン系粘着剤から選択される少なくとも一つの粘着剤を含んでもよい。ゴム系粘着剤は、例えば、ポリイソプレン、ポリイソブチレン(PIB)、ポリブタジエン、スチレン-ブタジエン-スチレンブロック共重合体、スチレン-イソプレン-スチレン(SIS)ブロック共重合体、スチレン-ブタジエンゴム、スチレン-イソプレンゴム、又はこれらの組み合わせである。このうち、薬物の皮膚透過性を高め、また、貼付剤の粘着性をより高めるという点から、SISブロック共重合体、PIB、又はこれらの組み合わせが好ましく、SISブロック共重合体とPIBの混合物であることがより好ましい。アクリル系粘着剤は、例えば、(メタ)アクリル酸、(メタ)アクリル酸-2-エチルヘキシル、(メタ)アクリル酸メチル、(メタ)アクリル酸ブチル、(メタ)アクリル酸ヒドロキシエチル等の(メタ)アクリルモノマーのうちの少なくとも1種を重合又は共重合させた粘着剤である。シリコーン系粘着剤は、例えば、ポリジメチルシロキサン、ポリメチルビニルシロキサン、及びポリメチルフェニルシロキサン等のシリコーンゴムを主成分とする。 The adhesive may include at least one adhesive selected from a rubber adhesive, an acrylic adhesive, and a silicone adhesive. Examples of rubber adhesives include polyisoprene, polyisobutylene (PIB), polybutadiene, styrene-butadiene-styrene block copolymer, styrene-isoprene-styrene (SIS) block copolymer, styrene-butadiene rubber, and styrene-isoprene. rubber, or a combination thereof. Among these, SIS block copolymer, PIB, or a combination thereof is preferable from the viewpoint of increasing the skin permeability of the drug and further increasing the adhesiveness of the patch. It is more preferable that there be. Examples of acrylic adhesives include (meth)acrylic acid, 2-ethylhexyl (meth)acrylate, methyl (meth)acrylate, butyl (meth)acrylate, and hydroxyethyl (meth)acrylate. This adhesive is made by polymerizing or copolymerizing at least one type of acrylic monomer. The silicone adhesive has silicone rubber such as polydimethylsiloxane, polymethylvinylsiloxane, and polymethylphenylsiloxane as a main component.

粘着剤の含有量は、ゴム系粘着剤の場合、貼付剤の粘着性の点から、粘着剤層の全質量に対して、10質量%~70質量%、10質量%~40質量%、15質量%~50質量%、15質量%~35質量%、又は30質量%~40質量%であってよい。アクリル系粘着剤又はシリコーン系粘着剤の場合、粘着剤の含有量は、粘着剤層の全質量に対して、50質量%~90質量%であってよい。 In the case of a rubber-based adhesive, the content of the adhesive is 10% by mass to 70% by mass, 10% to 40% by mass, 15% by mass, based on the total mass of the adhesive layer, from the viewpoint of adhesiveness of the patch. It may be from 15% to 35% by weight, or from 30% to 40% by weight. In the case of an acrylic adhesive or a silicone adhesive, the content of the adhesive may be 50% by mass to 90% by mass based on the total mass of the adhesive layer.

粘着剤層は、薬物の経皮吸収を促進するため、又は薬物の結晶が経時的に析出するのを防止するため等の目的で、さらに有機酸を含有してよい。有機酸としては、脂肪族モノカルボン酸(ギ酸、酢酸、プロピオン酸、酪酸、イソ酪酸、吉草酸、カプロン酸、エナント酸、カプリル酸、ノナン酸、カプリン酸、ラウリン酸、オレイン酸、リノール酸、リノレン酸、イソステアリン酸、ソルビン酸、ピルビン酸等)、脂肪族ジカルボン酸(シュウ酸、マロン酸、コハク酸、グルタル酸、アジピン酸、セバシン酸、マレイン酸、フマル酸、オキサロ酢酸等)、及び脂肪族トリカルボン酸(アコニット酸、プロパントリカルボン酸等)等の脂肪族カルボン酸、ヒドロキシ酸(グリコール酸、乳酸、タルトロン酸、グリセリン酸、ヒドロキシ酪酸、リンゴ酸、酒石酸、クエン酸、イソクエン酸、糖酸、グルコン酸、グルクロン酸、アスコルビン酸、エリソルビン酸等)、芳香族カルボン酸(安息香酸、没食子酸、サリチル酸、アセチルサリチル酸、フタル酸等)、その他の有機酸(メシル酸、ペシル酸等)、又は、これらの塩(例えば、ナトリウム塩等のアルカリ金属塩)が例示される。これら有機酸の中でも、薬物がジクロフェナクナトリウムである場合には、ジクロフェナクナトリウムの経皮吸収を促進し、ジクロフェナクナトリウムの結晶が経時的に析出するのを防止する点から、特に、クエン酸、オレイン酸、メシル酸、又はこれらのアルカリ金属塩が好ましい。これらの有機酸を含有することにより、十分な薬物の累積皮膚透過量がより確実に得られる。これらの有機酸は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。薬物の皮膚透過性を向上させ、かつ薬物の結晶が経時的に析出するのを防止する点から、有機酸の含有量は、粘着剤層の全質量に対して、0.01質量%~20質量%であってよく、0.1質量%~15質量%であってよく、0.2~13質量%であってよい。 The adhesive layer may further contain an organic acid for the purpose of promoting transdermal absorption of the drug or preventing crystals of the drug from precipitating over time. Examples of organic acids include aliphatic monocarboxylic acids (formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, nonanoic acid, capric acid, lauric acid, oleic acid, linoleic acid, linolenic acid, isostearic acid, sorbic acid, pyruvic acid, etc.), aliphatic dicarboxylic acids (oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, sebacic acid, maleic acid, fumaric acid, oxaloacetic acid, etc.), and fats. Aliphatic carboxylic acids such as tricarboxylic acids (aconitic acid, propanetricarboxylic acid, etc.), hydroxy acids (glycolic acid, lactic acid, tartronic acid, glyceric acid, hydroxybutyric acid, malic acid, tartaric acid, citric acid, isocitric acid, sugar acid, gluconic acid, glucuronic acid, ascorbic acid, erythorbic acid, etc.), aromatic carboxylic acids (benzoic acid, gallic acid, salicylic acid, acetylsalicylic acid, phthalic acid, etc.), other organic acids (mesylic acid, pesylic acid, etc.), or Examples of these salts include alkali metal salts such as sodium salts. Among these organic acids, when the drug is diclofenac sodium, citric acid, oleic acid, etc. , mesylic acid, or alkali metal salts thereof are preferred. By containing these organic acids, a sufficient amount of cumulative drug permeation through the skin can be more reliably obtained. These organic acids may be used alone or in combination of two or more. In order to improve the skin permeability of the drug and prevent the precipitation of drug crystals over time, the content of the organic acid is 0.01% by mass to 20% by mass based on the total mass of the adhesive layer. % by weight, and may be from 0.1% to 15% by weight, and from 0.2 to 13% by weight.

粘着剤層は、粘着付与剤、可塑剤又はその他の添加剤をさらに含んでいてよい。粘着付与剤は、例えば、脂環族飽和炭化水素樹脂、水添ロジンエステル、テルペン樹脂、又はこれらの組み合わせである。粘着付与剤の含有量は、粘着剤層の全質量に対して、例えば、5質量%~60質量%、10質量%~50質量%、25質量%~45質量%、又は30質量%~35質量%である。可塑剤は、例えば、流動パラフィン又は液状ポリブテンである。可塑剤の含有量は、粘着剤層の全質量に対して、例えば、7質量%~70質量%、10質量%~60質量%、又は11質量%~25質量%である。 The adhesive layer may further contain a tackifier, a plasticizer, or other additives. The tackifier is, for example, an alicyclic saturated hydrocarbon resin, a hydrogenated rosin ester, a terpene resin, or a combination thereof. The content of the tackifier is, for example, 5% to 60% by mass, 10% to 50% by mass, 25% to 45% by mass, or 30% to 35% by mass, based on the total mass of the adhesive layer. Mass%. Plasticizers are, for example, liquid paraffin or liquid polybutene. The content of the plasticizer is, for example, 7% to 70% by weight, 10% to 60% by weight, or 11% to 25% by weight based on the total weight of the adhesive layer.

粘着剤層は、1種の組成からなる単層であってよく、組成の異なる複数の層が積層してなる複層であってもよい。粘着剤層の全体の厚みは、貼付剤を適切に皮膚へ粘着させる点から、10μm~1000μmが好ましく、30μm~300μmがより好ましい。 The adhesive layer may be a single layer having one type of composition, or may be a multilayer formed by laminating a plurality of layers having different compositions. The total thickness of the adhesive layer is preferably 10 μm to 1000 μm, more preferably 30 μm to 300 μm, from the viewpoint of properly adhering the patch to the skin.

粘着剤層のプローブタック値は、30gF以上であることが好ましく、40gF以上であることがより好ましい。粘着剤層のプローブタック値は、例えば、43gF以上、44gF以上、53gF以上、61gF以上、68gF以上、又は71gF以上であってよい。プローブタック値が高いほど、貼付剤の付着性は向上する。皮膚への刺激を低減する観点から、プローブタック値は、2000gF以下、1500gF以下、又は1000gF以下であってよい。本明細書において、粘着剤層のプローブタック値は、ASTM D2979のプローブタック試験方法に準じて測定される。 The probe tack value of the adhesive layer is preferably 30 gF or more, more preferably 40 gF or more. The probe tack value of the adhesive layer may be, for example, 43 gF or more, 44 gF or more, 53 gF or more, 61 gF or more, 68 gF or more, or 71 gF or more. The higher the probe tack value, the better the adhesiveness of the patch. From the viewpoint of reducing skin irritation, the probe tack value may be 2000 gF or less, 1500 gF or less, or 1000 gF or less. In this specification, the probe tack value of the adhesive layer is measured according to the probe tack test method of ASTM D2979.

次に、支持体層について説明する。支持体層は、粘着剤層を保持する。支持体層の透湿度は400g/m・24時間以上である。このような高い透湿度の支持体層を用いると、皮膚に適用した貼付剤からDMSOが徐々に揮散するため、貼付剤の粘着性が向上し、貼付剤を長時間適用しても、剥がれ落ちにくい。透湿度は本来、水の透過性についての指標であるが、本発明者らは、透湿度の高い支持体は、高いDMSOの透過性(揮発性)をも有することを見出した。支持体層の透湿度は、例えば、422g/m・24時間以上、750g/m・24時間以上、2000g/m・24時間以上、2077g/m・24時間以上、4000g/m・24時間以上、5500g/m・24時間以上、5667g/m・24時間以上、又は8408g/m・24時間以上であってよい。透湿度の上限値は、20000g/m・24時間であってよい。支持体層の透湿度がこのような範囲にあると、DMSOが粘着剤層からより揮散しやすいため、貼付剤の粘着性の向上に、より効果的である。 Next, the support layer will be explained. The support layer holds the adhesive layer. The moisture permeability of the support layer is 400 g/m 2 ·24 hours or more. When such a support layer with high moisture permeability is used, DMSO gradually evaporates from the patch applied to the skin, improving the adhesiveness of the patch and preventing it from peeling off even if the patch is applied for a long time. Hateful. Although moisture permeability is originally an indicator of water permeability, the present inventors have found that a support with high moisture permeability also has high DMSO permeability (volatility). The moisture permeability of the support layer is, for example, 422 g/m 2 for 24 hours or more, 750 g/m 2 for 24 hours or more, 2000 g/m 2 for 24 hours or more, 2077 g/m 2 for 24 hours or more, 4000 g/m 2 - It may be 24 hours or more, 5500 g/m 2 · 24 hours or more, 5667 g/m 2 · 24 hours or more, or 8408 g/m 2 · 24 hours or more. The upper limit of moisture permeability may be 20,000 g/m 2 ·24 hours. When the moisture permeability of the support layer is within this range, DMSO is more easily volatilized from the adhesive layer, and is therefore more effective in improving the adhesiveness of the patch.

なお、本発明における支持体層の透湿度は、JIS Z0208:1976の規格(防湿包装材料の透湿度試験方法(カップ法))において定義される、40℃における透湿度を意味する。 The moisture permeability of the support layer in the present invention means the moisture permeability at 40° C. as defined in the JIS Z0208:1976 standard (moisture permeability testing method for moisture-proof packaging materials (cup method)).

支持体層は、繊維を布状(織布、不織布、又は編布)にしたものの、又は無孔性若しくは多孔性のフィルム(シート)の、単層体又は積層体であることが好ましい。支持体層の材質は、ポリエステル(ポリエチレンテレフタレート(PET)、ポリエチレンイソフタレート、ポリプロピレンテレフタレート、ポリプロピレンイソフタレート、ポリブチレンテレフタレート、又はポリエチレンナフタレート等)、ポリオレフィン(エチレン、プロピレン、酢酸ビニル、又はアクリロニトリル等のビニル系モノマーの重合体又は共重合体)、ポリアミド(ナイロン又は絹等)、ポリウレタン(PU)、又はセルロース(木綿又は麻等)から選ばれる1種以上の材質であることが好ましい。布(織布、不織布、又は編布)にはゴム組成物がコーティングされていてもよい。ゴム組成物は、ゴム系粘着剤を含む。ゴム系粘着剤は、例えば、ポリイソプレン、PIB、ポリブタジエン、スチレン-ブタジエン-スチレンブロック共重合体、SISブロック共重合体、スチレン-ブタジエンゴム、スチレン-イソプレンゴム、又はこれらの組み合わせである。ゴム組成物は、粘着付与剤を含んでもよい。粘着付与剤は、例えば、脂環族飽和炭化水素樹脂、水添ロジンエステル、テルペン樹脂、又はこれらの組み合わせである。また、ゴム組成物は、可塑剤、充填剤等の添加剤をさらに含んでもよい。支持体層の厚みは、例えば、0.1mm~2mmである。支持体層の目付けは、例えば、30g/m~200g/mである。本明細書において、支持体層の厚み及び目付けは、JIS L 1906:2000の規格に準じて測定される。 The support layer is preferably a single layer or a laminate of fibers in the form of cloth (woven fabric, nonwoven fabric, or knitted fabric), or nonporous or porous film (sheet). The material of the support layer is polyester (such as polyethylene terephthalate (PET), polyethylene isophthalate, polypropylene terephthalate, polypropylene isophthalate, polybutylene terephthalate, or polyethylene naphthalate), polyolefin (such as ethylene, propylene, vinyl acetate, or acrylonitrile). The material is preferably one or more selected from vinyl monomer polymers or copolymers), polyamides (nylon or silk, etc.), polyurethane (PU), or cellulose (cotton, hemp, etc.). The fabric (woven fabric, nonwoven fabric, or knitted fabric) may be coated with a rubber composition. The rubber composition includes a rubber adhesive. The rubber adhesive is, for example, polyisoprene, PIB, polybutadiene, styrene-butadiene-styrene block copolymer, SIS block copolymer, styrene-butadiene rubber, styrene-isoprene rubber, or a combination thereof. The rubber composition may also include a tackifier. The tackifier is, for example, an alicyclic saturated hydrocarbon resin, a hydrogenated rosin ester, a terpene resin, or a combination thereof. Moreover, the rubber composition may further contain additives such as a plasticizer and a filler. The thickness of the support layer is, for example, 0.1 mm to 2 mm. The basis weight of the support layer is, for example, 30 g/m 2 to 200 g/m 2 . In this specification, the thickness and basis weight of the support layer are measured according to the standard of JIS L 1906:2000.

支持体層が布状である場合、支持体層の縦方向(材料流れ方向)及び横方向(材料幅方向)のいずれの方向の50%モジュラス(JIS L 1018:1999)も、1N/50mm~12N/50mmであることが好ましい。50%モジュラスが12N/50mm以下である場合、皮膚の伸縮により貼付剤が受けるストレスがより小さいため、皮膚への付着性が良好となる。 When the support layer is cloth-like, the 50% modulus (JIS L 1018:1999) of the support layer in both the longitudinal direction (material flow direction) and the lateral direction (material width direction) is 1N/50mm ~ Preferably it is 12N/50mm. When the 50% modulus is 12 N/50 mm or less, the stress applied to the patch due to the expansion and contraction of the skin is smaller, resulting in good adhesion to the skin.

支持体層がフィルムである場合、材質はポリウレタンのような、高透湿性(高DMSO透過性)であることが好ましい。ポリウレタンからなるフィルムは、伸縮性に優れるため、貼付剤の、皮膚への付着性及び伸縮追従性を高める点から好ましい。 When the support layer is a film, the material is preferably highly moisture permeable (high DMSO permeability), such as polyurethane. A film made of polyurethane is preferable because it has excellent elasticity and improves the adhesion of the patch to the skin and the ability to follow elasticity.

支持体層は、例えば、ポリウレタンからなる不織布若しくはフィルム、ポリエチレンテレフタレートからなる編布、ゴム組成物でコーティングされたポリエステルの布又はこれらの組み合わせであることが好ましい。より具体的には、支持体層は、ポリウレタンからなるフィルムとポリウレタン繊維からなる不織布との積層体、PET繊維からなる不織布、又はゴム組成物でコーティングされたポリエステルの布であることが好ましい。 The support layer is preferably, for example, a nonwoven fabric or film made of polyurethane, a knitted fabric made of polyethylene terephthalate, a polyester fabric coated with a rubber composition, or a combination thereof. More specifically, the support layer is preferably a laminate of a polyurethane film and a nonwoven fabric made of polyurethane fibers, a nonwoven fabric made of PET fibers, or a polyester cloth coated with a rubber composition.

未使用の貼付剤において薬物が析出するのを防ぐ点から、貼付直前の貼付剤におけるDMSO濃度は、例えば、粘着剤層の全質量に対して、1質量%~20質量%、2質量%~12質量%、2質量%~10質量%、又は2質量%~8質量%であってよい。また、24時間貼付後の貼付剤におけるDMSO濃度は、0.1質量%~4質量%であることが好ましく、0.1質量%~1.5質量%であることがより好ましい。支持体層としては、このようなDMSO濃度の低下を達成することができるものが好ましい。より具体的には、貼付直前の貼付剤におけるDMSO濃度が2質量%~8質量%である場合、DMSO濃度の低下速度が0.08質量%/時間~0.16質量%/時間(すなわち、24時間あたりでは1.92質量%~3.84質量%の減少)となるような支持体層が好ましい。別の観点から、貼付直前の貼付剤におけるDMSO濃度が2質量%~8質量%である場合、DMSO濃度の半減期が5時間~24時間となるような支持体層が好ましい。このような条件を満たす支持体層であれば、24時間貼付後であっても、十分な付着性が維持される傾向にある。なお、上記の貼付剤のDMSO濃度の低下速度及び半減期は、いずれも30℃、65%RHの条件下で、支持体層が上向きになるように貼付剤を配置して、貼付剤のDMSO濃度の推移をガスクロマトグラフ法(GC)により測定することにより算出される。 In order to prevent drug precipitation in an unused patch, the DMSO concentration in the patch immediately before application is, for example, 1% to 20% by mass, 2% to 20% by mass, based on the total mass of the adhesive layer. It may be 12% by weight, 2% to 10% by weight, or 2% to 8% by weight. Further, the DMSO concentration in the patch after being applied for 24 hours is preferably 0.1% by mass to 4% by mass, more preferably 0.1% by mass to 1.5% by mass. The support layer is preferably one that can achieve such a reduction in DMSO concentration. More specifically, when the DMSO concentration in the patch immediately before application is 2% by mass to 8% by mass, the rate of decrease in DMSO concentration is 0.08% by mass/hour to 0.16% by mass/hour (i.e., It is preferable to use a support layer in which the amount decreases by 1.92% by mass to 3.84% by mass per 24 hours. From another point of view, when the DMSO concentration in the patch immediately before application is 2% by mass to 8% by mass, the support layer preferably has a half-life of DMSO concentration of 5 hours to 24 hours. If the support layer satisfies these conditions, sufficient adhesion will tend to be maintained even after 24 hours of attachment. The rate of decrease in DMSO concentration and half-life of the above-mentioned patch were determined under conditions of 30°C and 65% RH when the patch was placed with the support layer facing upward. It is calculated by measuring the change in concentration using gas chromatography (GC).

貼付剤は、例えば、次の方法により製造することができるが、これに限定されず、公知の方法を使用することができる。まず、粘着剤層を構成する各成分を所定の割合で混合して均一な溶解物を得る。次に、剥離可能なフィルム(剥離フィルム、離形ライナー)上に溶解物を所定の厚みで塗布して粘着剤層を形成する。次いで、粘着剤層が離形ライナーと支持体層とに挟まれるように、粘着剤層に支持体層を圧着する。最後に、所望の形状に切断することにより、貼付剤を得ることができる。この場合、離形ライナーは、貼付剤の適用時に除去される。 The patch can be manufactured, for example, by the following method, but the method is not limited thereto, and any known method can be used. First, each component constituting the adhesive layer is mixed in a predetermined ratio to obtain a uniform melt. Next, the melt is applied to a predetermined thickness onto a releasable film (release film, release liner) to form an adhesive layer. Next, the support layer is pressure-bonded to the adhesive layer so that the adhesive layer is sandwiched between the release liner and the support layer. Finally, a patch can be obtained by cutting into a desired shape. In this case, the release liner is removed upon application of the patch.

(貼付剤の調製)
以下の例において、別段の記載がない限り、貼付剤は次のように調製した。
1)粘着剤層の各成分を混和し、剥離フィルム(離型処理をしたPETフィルム)上に塗布した。これを乾燥させることでDMSOを所定量まで除去し、厚み100μmの粘着剤層(100g/m)を形成した。
2)粘着剤層上に支持体層を積層し、貼付剤を得た。貼付剤は適当な大きさに適宜裁断した。
(Preparation of patch)
In the examples below, unless otherwise specified, patches were prepared as follows.
1) Each component of the adhesive layer was mixed and coated on a release film (PET film subjected to mold release treatment). By drying this, DMSO was removed to a predetermined amount, and an adhesive layer (100 g/m 2 ) with a thickness of 100 μm was formed.
2) A support layer was laminated on the adhesive layer to obtain a patch. The patch was cut to an appropriate size.

(支持体層の透湿度の測定)
以下の例において、使用した支持体層の透湿度は、JIS Z0208に準じて、40℃、90%RHの測定条件で測定した。
(Measurement of moisture permeability of support layer)
In the following examples, the moisture permeability of the support layer used was measured under the measurement conditions of 40° C. and 90% RH in accordance with JIS Z0208.

(貼付剤の粘着性の評価)
以下の例において、別段の記載がない限り、貼付剤の粘着性は、次に示す180°剥離試験により評価した。
1)貼付剤から1cm×5cmの試験片を準備し、所定条件で所定時間保存した。
2)試験片から剥離フィルムを除去し、試験片をステンレス板に貼付した。
3)インストロン型引張試験機を用いて、試験片を30cm/分の速度でステンレス板から180°の方向に引き剥がし、剥離力(gF/cm)を測定した。
4)定常な剥離を示した区間での剥離力の積分値から、平均の剥離力(gF/cm)を算出した。高い剥離力は、優れた粘着性を意味する。
(Evaluation of adhesiveness of patch)
In the following examples, unless otherwise specified, the adhesiveness of the patch was evaluated by the following 180° peel test.
1) A 1 cm x 5 cm test piece was prepared from the patch and stored under predetermined conditions for a predetermined period of time.
2) The release film was removed from the test piece, and the test piece was attached to a stainless steel plate.
3) Using an Instron type tensile testing machine, the test piece was peeled off from the stainless steel plate in a direction of 180° at a speed of 30 cm/min, and the peeling force (gF/cm) was measured.
4) The average peeling force (gF/cm) was calculated from the integral value of the peeling force in the section showing steady peeling. High peel force means excellent adhesion.

(貼付剤の付着性の評価)
以下の例において、貼付剤の皮膚への付着性は、次に示す方法により評価した。被験者の皮膚に貼付剤を貼付した。24時間後、貼付剤の付着の程度を目視で観察した。貼付剤の面積の90%以上が皮膚に付着している状態である場合を「A」、それ以外の場合を「B」として評価した。
(Evaluation of adhesiveness of patch)
In the following examples, the adhesion of the patch to the skin was evaluated by the following method. A patch was applied to the subject's skin. After 24 hours, the degree of adhesion of the patch was visually observed. The evaluation was given as "A" if 90% or more of the area of the patch was attached to the skin, and "B" in other cases.

(試験例1)
表1に示す構成の貼付剤(プラセボ貼付剤)を調製した。表中、「PETフィルム」、「PETフィルム/PET不織布」、「PUフィルム/PU不織布」、及び「PET編布」とは、それぞれ、PETからなるフィルム、PETからなるフィルムとPET繊維からなる不織布との積層体、PUからなるフィルムとPU繊維からなる不織布との積層体、及びPETからなる編布を意味する。また、表1におけるゴム系粘着剤は、SISブロック共重合体とPIBの混合物であって、SISブロック共重合体とPIBを19:7の質量比で含む。「PET編布」としては、透湿度が5667g/m・24時間であり、縦方向の50%モジュラスが3.9N/50mmであり、かつ横方向の50%モジュラスが3.4N/50mmであるものを使用した(以下の例において同じ)。貼付剤を、30℃、65%RHのインキュベーター内に、支持体層が上向きになり、剥離フィルムが下向きになるように配置し、保存した。24時間後、貼付剤からDMSOを抽出し、GCにより定量した。この保存条件は、貼付剤を皮膚に24時間貼付した場合の環境を模した条件である。
(Test example 1)
A patch (placebo patch) having the composition shown in Table 1 was prepared. In the table, "PET film", "PET film/PET nonwoven fabric", "PU film/PU nonwoven fabric", and "PET knitted fabric" respectively refer to a film made of PET, a film made of PET, and a nonwoven fabric made of PET fibers. A laminate of a film made of PU and a nonwoven fabric made of PU fiber, and a knitted fabric made of PET. Further, the rubber adhesive in Table 1 is a mixture of an SIS block copolymer and PIB, and contains the SIS block copolymer and PIB in a mass ratio of 19:7. The "PET knitted fabric" has a moisture permeability of 5667 g/ m2.24 hours, a 50% modulus in the longitudinal direction of 3.9 N/50 mm, and a 50% modulus in the transverse direction of 3.4 N/50 mm. I used one (same in the example below). The patch was placed and stored in an incubator at 30° C. and 65% RH with the support layer facing upward and the release film facing downward. After 24 hours, DMSO was extracted from the patch and quantified by GC. These storage conditions simulate the environment in which the patch is applied to the skin for 24 hours.

結果を表1、図1、及び図2に示す。支持体層の透湿度が400g/m・24時間以上である参考例3及び4の貼付剤は、支持体層の透湿度が400g/m・24時間未満である参考例1及び2の貼付剤と比べて、24時間保存後のDMSO濃度が大きく低下した。透湿度の高い支持体層を有する貼付剤は、粘着剤層中におけるDMSO濃度の低下速度が高く(図1)、DMSO濃度の半減期が短い(図2)という関係がみられた。 The results are shown in Table 1, FIG. 1, and FIG. 2. The patches of Reference Examples 3 and 4 in which the support layer has a moisture permeability of 400 g/m 2.24 hours or more are the patches of Reference Examples 1 and 2 in which the support layer has a moisture permeability of less than 400 g/m 2.24 hours. Compared to the patch, the DMSO concentration after 24-hour storage was significantly reduced. A relationship was observed in which the patch having a support layer with high moisture permeability had a high rate of decrease in the DMSO concentration in the adhesive layer (Figure 1) and a short half-life of the DMSO concentration (Figure 2).

また、24時間同条件下に保存した貼付剤の粘着性を評価した。結果を表1に示す。支持体層の透湿度が400g/m・24時間以上である参考例3及び4の貼付剤は、支持体層の透湿度が400g/m・24時間未満である参考例1及び2の貼付剤と比べて、24時間保存後の粘着性(剥離力)が良好であった。 In addition, the adhesiveness of the patch stored under the same conditions for 24 hours was evaluated. The results are shown in Table 1. The patches of Reference Examples 3 and 4 in which the support layer has a moisture permeability of 400 g/m 2.24 hours or more are the patches of Reference Examples 1 and 2 in which the support layer has a moisture permeability of less than 400 g/m 2.24 hours. The adhesiveness (peel strength) after 24-hour storage was better than that of the patch.

さらに、表1に示す構成の貼付剤の24時間後の付着性を評価した。結果を表1に示す。支持体層の透湿度が400g/m・24時間以上である参考例3及び4の貼付剤は、24時間貼付後の付着性が良好であった。 Furthermore, the adhesion of the patches having the configurations shown in Table 1 after 24 hours was evaluated. The results are shown in Table 1. The patches of Reference Examples 3 and 4, in which the moisture permeability of the support layer was 400 g/m 2 ·24 hours or more, had good adhesion after 24 hours of application.

Figure 0007366166000001
Figure 0007366166000001

(試験例2)
表2に示す構成の貼付剤を調製した。表2におけるゴム系粘着剤は、SISブロック共重合体とPIBの混合物であって、SISブロック共重合体とPIBを19:7の質量比で含む。実施例2、7~9の貼付剤の粘着性を、ASTM D2979のプローブタック試験方法に準じて以下の条件で測定したプローブタック値により評価した。高いプローブタック値は、優れた粘着性を意味する。
試験機:タッキング試験機(レスカ)
プローブ部先端材質:ステンレス
接着面の直径:5mm
引離し速度:2mm/秒
接着荷重:200gF/cm
接着時間:1秒
(Test example 2)
A patch having the structure shown in Table 2 was prepared. The rubber adhesive in Table 2 is a mixture of SIS block copolymer and PIB, and contains the SIS block copolymer and PIB in a mass ratio of 19:7. The adhesiveness of the patches of Examples 2 and 7 to 9 was evaluated by the probe tack value measured under the following conditions according to the probe tack test method of ASTM D2979. A high probe tack value means excellent tack.
Test machine: Tacking test machine (Resca)
Probe tip material: Stainless steel Diameter of adhesive surface: 5mm
Peeling speed: 2mm/sec Adhesive load: 200gF/ cm2
Adhesion time: 1 second

また、実施例1~15及び比較例1~3の貼付剤を、健常な成人男性の腰背部に1枚ずつ貼付し、24時間後の付着性を評価した。結果を表2に示す。支持体層の透湿度が400g/m・24時間以上である実施例1~15の貼付剤は、24時間貼付後の付着性が良好であった。 In addition, each patch of Examples 1 to 15 and Comparative Examples 1 to 3 was applied to the lower back of a healthy adult male, and the adhesion was evaluated after 24 hours. The results are shown in Table 2. The patches of Examples 1 to 15, in which the moisture permeability of the support layer was 400 g/m 2 for 24 hours or more, had good adhesion after 24 hours of application.

さらに、実施例2の貼付剤を、30℃、65%RHのインキュベーター内に、支持体層が上向きになるように配置し、保存した。24時間経過後、粘着剤層中のDMSO濃度(質量%)をGCにより定量し、DMSO濃度の推移を調べた。24時間経過後のDMSO濃度は、粘着剤層の全質量に対して1.2質量%であり、これは、初期(保存前)のDMSO濃度100%に対して33%である。DMSO濃度の変化から算出したDMSO濃度の低下速度は0.1質量%/時間であり、半減期は15時間であった。 Furthermore, the patch of Example 2 was placed and stored in an incubator at 30° C. and 65% RH with the support layer facing upward. After 24 hours had passed, the DMSO concentration (mass %) in the adhesive layer was determined by GC, and the change in DMSO concentration was examined. The DMSO concentration after 24 hours was 1.2% by mass based on the total mass of the adhesive layer, which was 33% with respect to the initial (before storage) DMSO concentration of 100%. The rate of decrease in DMSO concentration calculated from the change in DMSO concentration was 0.1% by mass/hour, and the half-life was 15 hours.

Figure 0007366166000002
Figure 0007366166000002

(試験例3)
表3に示す構成の貼付剤を調製した。表3に示す構成の貼付剤について、試験例2と同様の方法でプローブタック値を測定し、粘着性を評価した。表3におけるゴム系粘着剤は、SISブロック共重合体とPIBの混合物であって、SISブロック共重合体とPIBを19:7の質量比で含む。表3における「ゴム/ポリエステル布」とは、ゴム組成物でコーティングされたポリエステルの布を意味する。実施例16の貼付剤におけるPUフィルム(透湿度786g/m・24時間)、並びに、実施例17、19及び20の貼付剤におけるPUフィルム(透湿度8408g/m・24時間)は、それぞれ3M社の「3M CoTran 9701 Backing」及び「3M CoTran 9700」である。
(Test example 3)
A patch having the structure shown in Table 3 was prepared. The probe tack value of the patch having the structure shown in Table 3 was measured in the same manner as in Test Example 2, and the tackiness was evaluated. The rubber adhesive in Table 3 is a mixture of SIS block copolymer and PIB, and contains the SIS block copolymer and PIB in a mass ratio of 19:7. "Rubber/polyester fabric" in Table 3 means a polyester fabric coated with a rubber composition. The PU film in the patch of Example 16 (moisture permeability 786 g/m 2 24 hours) and the PU film in the patches of Examples 17, 19 and 20 (moisture permeability 8408 g/m 2 24 hours) were They are "3M CoTran 9701 Backing" and "3M CoTran 9700" from 3M Company.

実施例16~19、並びに比較例4及び5の貼付剤について、24時間後の付着性を評価した。結果を表3に示す。また、これらの実施例及び比較例の貼付剤を、30℃、65%RHのインキュベーター内に、支持体層が上向きになるように配置し、保存した。24時間経過後、粘着剤層中のDMSO濃度(質量%)をGCにより定量し、DMSO濃度の推移を調べた。結果を表3に示す。支持体層の透湿度が400g/m・24時間以上である実施例16~19の貼付剤は、24時間貼付後の付着性が良好であった。 The adhesiveness of the patches of Examples 16 to 19 and Comparative Examples 4 and 5 was evaluated after 24 hours. The results are shown in Table 3. Further, the patches of Examples and Comparative Examples were placed and stored in an incubator at 30° C. and 65% RH with the support layer facing upward. After 24 hours had passed, the DMSO concentration (mass %) in the adhesive layer was determined by GC, and the change in DMSO concentration was examined. The results are shown in Table 3. The patches of Examples 16 to 19, in which the moisture permeability of the support layer was 400 g/m 2 for 24 hours or more, had good adhesion after 24 hours of application.

Figure 0007366166000003
Figure 0007366166000003

Claims (12)

支持体層と支持体層上に積層された粘着剤層とを備え、
支持体層の透湿度が400g/m・24時間以上であり、
粘着剤層が、薬物と、ジメチルスルホキシドと、粘着剤とを含む、貼付剤であって、
貼付直前のジメチルスルホキシドの濃度が、粘着剤層の全質量に対して2質量%~12質量%であり、24時間貼付後のジメチルスルホキシドの濃度が、粘着剤層の全質量に対して0.1質量%~4質量%である、貼付剤。
Comprising a support layer and an adhesive layer laminated on the support layer,
The moisture permeability of the support layer is 400 g/m 2 24 hours or more,
A patch in which the adhesive layer includes a drug, dimethyl sulfoxide, and an adhesive,
The concentration of dimethyl sulfoxide immediately before application is 2% by mass to 12% by mass relative to the total mass of the adhesive layer, and the concentration of dimethyl sulfoxide after application for 24 hours is 0.0% relative to the total mass of the adhesive layer. A patch having a concentration of 1% by mass to 4% by mass.
支持体層の透湿度が750g/m・24時間以上である、請求項1に記載の貼付剤。 The adhesive patch according to claim 1, wherein the support layer has a moisture permeability of 750 g/m 2 ·24 hours or more. 支持体層の透湿度が2000g/m・24時間以上である、請求項1に記載の貼付剤。 The adhesive patch according to claim 1, wherein the support layer has a moisture permeability of 2000 g/m 2 ·24 hours or more. 粘着剤層が、ゴム系粘着剤、アクリル系粘着剤及びシリコーン系粘着剤から選択される少なくとも一つの粘着剤を含む、請求項1~3のいずれか一項に記載の貼付剤。 The adhesive patch according to any one of claims 1 to 3, wherein the adhesive layer contains at least one adhesive selected from a rubber adhesive, an acrylic adhesive, and a silicone adhesive. 粘着剤層が、スチレン-イソプレン-スチレンブロック共重合体を含む、請求項1~3のいずれか一項に記載の貼付剤。 The adhesive patch according to any one of claims 1 to 3, wherein the adhesive layer contains a styrene-isoprene-styrene block copolymer. 薬物が、ケトプロフェン、ジクロフェナクナトリウム、及びインドメタシンからなる群より選択される1種以上の薬物である、請求項1~5のいずれか一項に記載の貼付剤。 The patch according to any one of claims 1 to 5, wherein the drug is one or more drugs selected from the group consisting of ketoprofen, diclofenac sodium, and indomethacin. 粘着剤層がさらに有機酸を含む、請求項6に記載の貼付剤。 The adhesive patch according to claim 6, wherein the adhesive layer further contains an organic acid. 貼付直前のジメチルスルホキシドの濃度が、粘着剤層の全質量に対して2質量%~10質量%である、請求項1~7のいずれか一項に記載の貼付剤。 The adhesive patch according to any one of claims 1 to 7 , wherein the concentration of dimethyl sulfoxide immediately before application is 2% by mass to 10% by mass based on the total mass of the adhesive layer. 貼付直前のジメチルスルホキシドの濃度が、粘着剤層の全質量に対して2質量%~8質量%である、請求項に記載の貼付剤。 The adhesive patch according to claim 8 , wherein the concentration of dimethyl sulfoxide immediately before application is 2% by mass to 8% by mass based on the total mass of the adhesive layer. 貼付剤におけるジメチルスルホキシドの濃度を低下させる方法であって、
貼付剤は、支持体層と支持体層上に積層された粘着剤層とを備え、
粘着剤層は、薬物と、ジメチルスルホキシドと、粘着剤とを含み、
前記方法は、支持体層として透湿度が400g/m・24時間以上である支持体層を用いることを含み、
貼付直前の貼付剤におけるジメチルスルホキシドの濃度が、粘着剤層の全質量に対して2質量%~12質量%である、方法。
A method for reducing the concentration of dimethyl sulfoxide in a patch, the method comprising:
The patch includes a support layer and an adhesive layer laminated on the support layer,
The adhesive layer includes a drug, dimethyl sulfoxide, and an adhesive,
The method includes using a support layer having a moisture permeability of 400 g/m 2 24 hours or more as the support layer ,
A method in which the concentration of dimethyl sulfoxide in the patch immediately before application is 2% by mass to 12% by mass based on the total mass of the adhesive layer .
24時間貼付後の貼付剤におけるジメチルスルホキシドの濃度が、粘着剤層の全質量に対して0.1質量%~4質量%となる、請求項10に記載の方法。 The method according to claim 10 , wherein the concentration of dimethyl sulfoxide in the patch after being applied for 24 hours is 0.1% by mass to 4% by mass based on the total mass of the adhesive layer. 粘着剤層がさらに有機酸を含む、請求項10又は11に記載の方法。 The method according to claim 10 or 11 , wherein the adhesive layer further contains an organic acid.
JP2022002170A 2016-12-28 2022-01-11 patch Active JP7366166B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174989A JP2023184531A (en) 2016-12-28 2023-10-10 patch

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2016256702 2016-12-28
JP2016256702 2016-12-28
JP2018559525A JP7069042B2 (en) 2016-12-28 2017-12-26 Patch
PCT/JP2017/046697 WO2018124089A1 (en) 2016-12-28 2017-12-26 Patch

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018559525A Division JP7069042B2 (en) 2016-12-28 2017-12-26 Patch

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174989A Division JP2023184531A (en) 2016-12-28 2023-10-10 patch

Publications (2)

Publication Number Publication Date
JP2022036194A JP2022036194A (en) 2022-03-04
JP7366166B2 true JP7366166B2 (en) 2023-10-20

Family

ID=62707631

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559525A Active JP7069042B2 (en) 2016-12-28 2017-12-26 Patch
JP2022002170A Active JP7366166B2 (en) 2016-12-28 2022-01-11 patch
JP2023174989A Pending JP2023184531A (en) 2016-12-28 2023-10-10 patch

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018559525A Active JP7069042B2 (en) 2016-12-28 2017-12-26 Patch

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174989A Pending JP2023184531A (en) 2016-12-28 2023-10-10 patch

Country Status (8)

Country Link
US (2) US11020356B2 (en)
EP (1) EP3563840B1 (en)
JP (3) JP7069042B2 (en)
KR (1) KR102358377B1 (en)
CN (1) CN110114064A (en)
ES (1) ES2893527T3 (en)
TW (1) TWI743283B (en)
WO (1) WO2018124089A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021015353A2 (en) 2019-02-06 2021-10-05 Venthera, Inc. TOPICAL PHOSFOINOSITIDE 3-KINASE INHIBITORS
CN113474043B (en) * 2019-02-27 2024-05-14 久光制药株式会社 Patch agent
JP6744511B1 (en) * 2020-02-12 2020-08-19 久光製薬株式会社 Patch containing sodium diclofenac
JP6744512B1 (en) * 2020-02-12 2020-08-19 久光製薬株式会社 Patch containing sodium diclofenac
JP6761553B1 (en) * 2020-02-12 2020-09-23 久光製薬株式会社 Diclofenac sodium-containing patch
JP2023538265A (en) * 2020-08-04 2023-09-07 ベンセラ,インコーポレイティド Formulation of phosphoinositide 3-kinase inhibitors
US11872320B2 (en) 2021-02-25 2024-01-16 Hisamitsu Pharmaceutical Co., Inc. Method for treating osteoarthritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137699A1 (en) 2009-05-29 2010-12-02 株式会社イノアック技術研究所 Patch material
WO2011136330A1 (en) 2010-04-30 2011-11-03 ニチバン株式会社 Adhesive patch and use thereof
WO2013191128A1 (en) 2012-06-20 2013-12-27 久光製薬株式会社 Skin patch

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047732C (en) * 1995-04-10 1999-12-29 浙江省医学科学院 Transcutaneous huperzing sticker
US5702720A (en) 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
JPH11322590A (en) 1998-05-13 1999-11-24 Teijin Ltd New adhesive and patch
WO2002036103A1 (en) * 2000-11-06 2002-05-10 Samyang Corporation Transdermal drug delivery system with improved water absorbability and adhesion properties
US7202322B2 (en) * 2002-11-08 2007-04-10 Noveon, Inc. Heat resistant high moisture vapor transmission thermoplastic polyurethane
WO2004047820A1 (en) * 2002-11-27 2004-06-10 Hisamitsu Pharmaceutical Co., Inc. Warm poultice
GB2396109B (en) * 2002-12-12 2006-04-19 Johnson & Johnson Medical Ltd Absorbent multilayer hydrogel wound dressings
AU2003292830A1 (en) 2002-12-26 2004-07-22 Kowa Co., Ltd. Adhesive patch
KR100682729B1 (en) * 2004-06-15 2007-02-15 (주)아모레퍼시픽 Novel transdermal preparation and its producing method
JP2006288887A (en) 2005-04-13 2006-10-26 Nitto Denko Corp Adhesive skin patch
JP2007015963A (en) * 2005-07-06 2007-01-25 Hisamitsu Pharmaceut Co Inc Patch
HUE047985T2 (en) * 2006-08-04 2020-05-28 Hisamitsu Pharmaceutical Co Adhesive preparation
EP2246059B1 (en) 2008-01-31 2014-06-04 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
EP2196197A1 (en) 2008-12-15 2010-06-16 Bouty S.P.A. Antiviral patch
JP5860201B2 (en) 2010-02-12 2016-02-16 久光製薬株式会社 Transdermal absorption preparation and method for producing the same
WO2012048455A1 (en) * 2010-10-12 2012-04-19 武汉大学 Transdermal absorption patch of antiviral drug and its preparation method
EP2809307B1 (en) * 2012-01-31 2017-12-20 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
JP5307931B1 (en) * 2012-12-27 2013-10-02 久光製薬株式会社 Patch and method for producing the same
EP2961360A4 (en) 2013-02-26 2017-02-15 Parapatch, Inc. Systems and methods for treating female incontinence and pelvic nerve dysfunction
WO2014148582A1 (en) 2013-03-21 2014-09-25 ニチバン株式会社 Solventless polyurethane-based adhesive

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010137699A1 (en) 2009-05-29 2010-12-02 株式会社イノアック技術研究所 Patch material
WO2011136330A1 (en) 2010-04-30 2011-11-03 ニチバン株式会社 Adhesive patch and use thereof
WO2013191128A1 (en) 2012-06-20 2013-12-27 久光製薬株式会社 Skin patch

Also Published As

Publication number Publication date
EP3563840B1 (en) 2021-09-01
KR20190085972A (en) 2019-07-19
EP3563840A4 (en) 2020-07-29
WO2018124089A1 (en) 2018-07-05
CN110114064A (en) 2019-08-09
JP2023184531A (en) 2023-12-28
JPWO2018124089A1 (en) 2019-10-31
US20190350874A1 (en) 2019-11-21
ES2893527T3 (en) 2022-02-09
US20210251913A1 (en) 2021-08-19
TW201828931A (en) 2018-08-16
TWI743283B (en) 2021-10-21
JP2022036194A (en) 2022-03-04
KR102358377B1 (en) 2022-02-03
US11020356B2 (en) 2021-06-01
EP3563840A1 (en) 2019-11-06
JP7069042B2 (en) 2022-05-17

Similar Documents

Publication Publication Date Title
JP7366166B2 (en) patch
JP6005742B2 (en) Patch
JP4873871B2 (en) Adhesives and patches
JP4660858B2 (en) Transdermal preparation
JP6556873B2 (en) Transdermal absorption preparation
JP5870350B2 (en) Bisoprolol transdermal administration device
JP5738531B2 (en) Patch
KR102477081B1 (en) Diclofenac sodium containing patch
KR102477521B1 (en) Diclofenac sodium containing patch
CA2735634C (en) Patch preparation and production method thereof
WO2004019930A1 (en) Pasting agent
JP5386205B2 (en) Transdermal patch
JP2024099065A (en) Aqueous patch
JP2019156720A (en) Patches

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230606

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231010

R150 Certificate of patent or registration of utility model

Ref document number: 7366166

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150